TAK : SQUARE ROOT / POSITION TRADE
There are reasons to be optimistic for the longer-term growth with Takeda also being a diversified COVID vaccine play.
Exploring further, the company has a multi-thronged approach to the problem, first as a treatment developer undergoing clinical Phase 2 trials using plasma technology, second as a manufacturer through a license agreement with Novavax's (NASDAQ: NVAX ) COVID-19 vaccine candidate and finally, as a distributor in a three-way agreement with the Japanese government for Moderna's (NASDAQ: MRNA ) vaccine.
Source : Chetan Woodun, SeekingAlpha
read full article here : https://seekingalpha.com/article/4397133...